Literature DB >> 12898445

Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects.

Scott E Kellerman1, Debra L Hanson, A D McNaghten, Patricia L Fleming.   

Abstract

We determined incidence and risk factors for acute and chronic hepatitis B virus (HBV) infection and HBV vaccination rates among human immunodeficiency virus (HIV)-infected subjects from the Adult/Adolescent Spectrum of HIV Disease Project, during 1998-2001. Among 16,248 HIV-infected patients receiving care, the incidence of acute HBV was 12.2 cases/1000 person-years (316 cases), was higher among black subjects (rate ratio [RR], 1.4; 95% confidence interval [CI], 1.0-2.0), subjects with alcoholism (RR, 1.7; 95% CI, 1.2-2.3), subjects who had recently injected drugs (RR, 1.6; 95% CI, 1.1-2.4), and subjects with a history of AIDS-defining conditions (RR, 1.5; 95% CI, 1.2-1.9) and was lower in those taking either antiretroviral therapy (ART) with lamivudine (RR, 0.5; 95% CI, 0.4-0.6), ART without lamivudine (RR, 0.5; 95% CI, 0.3-0.7), or >/=1 dose of HBV vaccine (14% of subjects) (RR, 0.6; 95% CI, 0.4-0.9). Prevalence of chronic HBV was 7.6% among unvaccinated subjects. HBV rates in this population were much higher than those in the general population, and vaccination levels were low. HBV remains an important cause of comorbidity in HIV-infected persons, but ART and vaccination are associated with decreased disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12898445     DOI: 10.1086/377135

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  78 in total

1.  Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters.

Authors:  Helen M Chun; Mollie P Roediger; Katherine Huppler Hullsiek; Chloe L Thio; Brian K Agan; William P Bradley; Sheila A Peel; Linda L Jagodzinski; Amy C Weintrob; Anuradha Ganesan; Glenn Wortmann; Nancy F Crum-Cianflone; Jason D Maguire; Michael L Landrum
Journal:  J Infect Dis       Date:  2011-12-05       Impact factor: 5.226

Review 2.  Insights into human immunodeficiency virus-hepatitis B virus co-infection in India.

Authors:  Runu Chakravarty; Ananya Pal
Journal:  World J Virol       Date:  2015-08-12

Review 3.  Viral hepatitis in HIV infection.

Authors:  Margaret James Koziel; Marion G Peters
Journal:  N Engl J Med       Date:  2007-04-05       Impact factor: 91.245

Review 4.  Hepatitis B virus vaccination in HIV-infected people: A review.

Authors:  François-Xavier Catherine; Lionel Piroth
Journal:  Hum Vaccin Immunother       Date:  2017-02-16       Impact factor: 3.452

5.  Update on Hepatitis B and C Coinfection in HIV.

Authors:  Patrick Yachimski; Raymond T Chung
Journal:  Curr Infect Dis Rep       Date:  2005-07       Impact factor: 3.725

Review 6.  Epidemiology, Natural History, and Treatment of Hepatitis Delta Virus Infection in HIV/Hepatitis B Virus Coinfection.

Authors:  Nicole D Ferrante; Vincent Lo Re
Journal:  Curr HIV/AIDS Rep       Date:  2020-08       Impact factor: 5.071

7.  The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patients.

Authors:  Joe Sasadeusz; Jennifer Audsley; Anne Mijch; Rachel Baden; Jose Caro; Hermeyone Hunter; Gail Matthews; Moira A McMahon; Susan A Olender; Robert F Siliciano; Sharon R Lewin; Chloe L Thio
Journal:  AIDS       Date:  2008-05-11       Impact factor: 4.177

Review 8.  HIV/HBV coinfection in children and antiviral therapy.

Authors:  Sara A Healy; Sonia Gupta; Ann J Melvin
Journal:  Expert Rev Anti Infect Ther       Date:  2013-03       Impact factor: 5.091

Review 9.  The role of viral co-infection in HIV-associated non-AIDS-related cancers.

Authors:  David J Riedel; Lydia S Tang; Anne F Rositch
Journal:  Curr HIV/AIDS Rep       Date:  2015-09       Impact factor: 5.071

Review 10.  Emerging challenges in managing hepatitis B in HIV patients.

Authors:  Vincent Soriano; Pablo Labarga; Carmen de Mendoza; José M Peña; José V Fernández-Montero; Laura Benítez; Isabella Esposito; Pablo Barreiro
Journal:  Curr HIV/AIDS Rep       Date:  2015-09       Impact factor: 5.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.